Politics hindering SARS work by Hsieh,  Y.H.
Sir — Your News story “Taiwan left
isolated in fight against SARS” (Nature
422, 652; 2003) highlights a problem
scientists here have faced for years. I was
invited to a workshop on mathematical
ecology in Trieste in 1988, arriving only to
find myself excluded from the list of
participants and not allowed to give a talk. 
Upon inquiry, I was told by the local
organizer that “officially” I was not present
at the workshop, co-sponsored by the
International Atomic Energy Agency 
and UNESCO, owing to a protest by the
Chinese Embassy in Rome after I had been
invited. Apparently, unlike scientists from
anywhere else, all Chinese scientists had 
to be recommended by the Chinese
government to attend that workshop, and
since Taiwan was considered to be part 
of China, I could not attend without
permission from the Chinese government. 
The SARS epidemic illustrates that
being politically correct in scientific
matters does more than just inconvenience
a few Taiwanese scientists. Indeed, with the
official global death toll from SARS at 643
by 19 May and rising fast, one can only
speculate how many lives could have been
saved had the health officials in Hong
Kong been a little less worried about 
being politically correct in dealing with 
the emergence of this epidemic.  
It is incredible that, even now, with the
SARS death toll in Hong Kong having
reached 247 by 18 May, officials there still
refuse to link the problem with Hong
Kong’s proximity to Guangdong Province
in China, where similar symptoms have
been appearing since November. Almost
all early infections in Hong Kong can be
traced to recent travellers from China or
people in close contact with them. 
The World Health Organization sent
two epidemiologists to Taiwan to assess the
situation on 3 May. Meanwhile, left to fight
SARS alone, Taiwan had a threefold rise in
the number of cases in April and by 19 May
had had 344 probable cases and 40 deaths.
Unfortunately, the Hong Kong
government seems more preoccupied with
how it looks to China and the rest of the
world than with saving lives.
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Taiwan has been left to fight its outbreak with little help.
Politics hindering SARS workEmbryos aren’t essentialto stem-cell research 
Sir — Your Editorial “Disease insights
from stem cells” (Nature 422, 787; 2003)
gives the impression that most US
scientists support human embryonic stem-
cell research. Not everybody would agree; I
would like to state a less reported view. 
The suggestion made by some that
cloned human embryos will provide
otherwise unobtainable cells for disease
research misleads the public. There are
available countless cell lines derived from a
wide variety of normal and diseased human
tissues. A greater concern is the practice of
understating the scientific challenges of
using human embryos to produce mature
adult tissues in vitro or in vivo. For embry-
onic stem cells to make adult tissues, they
must first be converted into adult stem
cells. All the fuss over embryonic stem cells
has damaged public enthusiasm for any
type of stem-cell research. 
The US Congress should target as much
as $200 million of funding for research
over the next five years to realize the
promise of stem cells for human therapies.
This would provide enough money for
several projects at each of the 18 National
Institutes of Health (NIH). This cost is 
a small fraction — less than 1% — of 
the present NIH budget (more than 
$27 billion). Both adult stem-cell research
and non-human embryonic stem-cell
research should be supported. Non-
human research might one day yield
methods of reprogramming human cells 
to early developmental states without
creating or destroying human embryos. 
Congress should motivate stem-cell
scientists to do what is in the best interest
of the public. This is a necessary tension to
ensure the long-term quality of the publicly
funded research enterprise. As for human
therapeutic cloning, the US public has been
waiting a long time for leadership that is
both moral and based on good science. In
the long run, the best interest of the public
will also be the best interest of scientists. 
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US federal funding ban
puts babies at risk
Sir — We wholeheartedly agree with your
Editorial “Reining in assisted reproduction”
(Nature 422, 647; 2003) that more research
is needed to identify and evaluate the risks
that assisted reproduction may pose to
children and their mothers. 
In the United States, a ban on federal
funding for embryo research makes this
work especially difficult. Lifting this ban
would both enable more outcome studies
and ensure that research on new
treatments would be subject to federal
supervision and would be conducted in
accordance with human-research subject
protections under the common rule. 
In the United Kingdom and other
European countries, patients benefit from
state-supported healthcare systems that
subsidize and regulate the treatment for
infertility and assisted-reproductive
technologies. Unfortunately, most patients
in the United States pay for their expensive
treatments out of their own pockets.
Sometimes, parents’ desire to maximize
their chances of having a baby and their
interest in minimizing risk to themselves
and their offspring are in conflict. 
We have doubts as to whether a 
system analogous to the United 
Kingdom’s Human Fertilisation and
Embryology Authority is appropriate 
in the United States, where citizens
fervently guard their rights to privacy 
and reproductive choice. 
Many would see a government body
with the power to dictate treatment
choices as an unwarranted imposition and
intrusion, especially because the
government does not subsidize payment
for their treatment. 
Proactive, responsible self-regulation is
the key to ensuring patient safety. The
American Society for Reproductive
Medicine (ASRM) guides medical 
practice and research and keeps members
abreast of the ethical issues arising daily
in reproductive medicine; the Society 
for Assisted Reproductive Technology
(SART) sets the standards for assisted-
reproductive technology clinics, including
laboratory certification, reporting of 
clinic success rates and compliance 
with the ASRM guidelines. This voluntary
yet effective procedure reflects the
dedication of our members to assuring
safety, efficacy and confidentiality for 
all our patients. 
We hope that the US government 
will one day fund research in this field,
with accompanying protection. In the
meantime, we appreciate our international
colleagues whose research informs our
own work. 
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